Arthneeti
All Q3 FY26 results →
C

Cipla Ltd

Q3 FY26Pharmaceuticals & Biotechnology

Cipla Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,432
Market cap₹1.2L Cr
P/E32.7
Updated23 Aug 2026
Read4 min read

The short version

Upcoming launches in the US (including four significant respiratory launches and generic Victoza) are expected to drive sustainable long-term growth and help cushion decline from legacy products like Lenalidomide. FY’26 EBITDA margin expected to land around 21%, slightly affected by lower-than-anticipated Lanreotide sales and the end of generic Revlimid billing cycle.

From Cipla Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Upcoming launches in the US (including four significant respiratory launches and generic Victoza) are expected to drive sustainable long-term growth and help cushion decline from legacy products like Lenalidomide.
  • One-India business showed strong 10% YoY growth, with a focus on execution to sustain momentum and outperform the market in both branded and trade generics.
  • Chronic therapies like diabetes, cardiac, respiratory, and urology are key growth drivers.
  • Expansion in consumer health with leading brands and distribution growth.
  • In EMEU, sustained growth with over $100 million quarterly revenue and margin stability.
  • South Africa private market showing strong secondary growth of 6.3%, with normalization expected post channel destocking.

2 more points from Cipla Ltd's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what Cipla Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Recent capital commitment of Rs. 1,100 crores related to the Galvus perpetual license and in-house manufacturing (Page 20).
  • Ongoing investments in manufacturing derisking and readiness for upcoming product launches, including US facilities (Pages 5, 16).
  • Minor capital expenses include lab equipment purchases (Page 16).
  • Continuous improvement programs focused on cost optimization and operating overhead pruning underway, expected to yield benefits starting next year (Page 16).

2 more points from Cipla Ltd's call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Cipla Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript of Cipla Limited's Q3 FY26 earnings call dated January 23, 2026, does not explicitly mention details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - Product launches and pipeline updates including peptides and respiratory assets. - Market performance in different regions such as the US, South Africa, and EMEU.

2 more points from Cipla Ltd's call on order book

Pro opens every point from 15K+ earnings calls

Cipla Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹6.5K Cr, net profit ₹543 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Cipla's management said in earlier quarters

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cipla Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cipla Ltd Q3 FY26 results?

Upcoming launches in the US (including four significant respiratory launches and generic Victoza) are expected to drive sustainable long-term growth and help cushion decline from legacy products like Lenalidomide. FY’26 EBITDA margin expected to land around 21%, slightly affected by lower-than-anticipated Lanreotide sales and the end of generic Revlimid billing cycle.

What is Cipla Ltd share price analysis?

Cipla Ltd currently shows a neutral. The stock trades at a P/E of 32.7 with a market cap of ₹117,139 Cr. Investors should review the full earnings analysis for detailed insights.

Is Cipla Ltd planning capital expenditure?

Recent capital commitment of Rs.

Keep Cipla Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.